Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 10:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 248 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Recruiting Not applicable Interventional

Neurologic Stem Cell Treatment Study

NCT02795052
Conditions
Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Interventions
Intravenous and Intranasal BMSC
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Conditions
Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia, Paget Disease of Bone, Frontotemporal Dementia, Myopathy
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2030
U.S. locations
1
States / cities
Irvine, California
Conditions
Predicted Tauopathies, Including, Progressive Supranuclear Palsy, Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17, Corticobasal Degeneration Syndrome, Progressive Nonfluent Aphasia
Interventions
davunetide (AL-108, NAP), Placebo nasal spray
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
Acamprosate calcium
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Primary Progressive Aphasia, Apraxia of Speech
Interventions
high-definition transcranial direct current stimulation (HD-tDCS)
Device
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Frontotemporal Dementia, Behavioral Variant Frontotemporal Dementia
Interventions
Assessments
Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Boca Raton, Florida + 8 more
Conditions
Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, Cortico Basal Degeneration, Posterior Cortical Atrophy (PCA), Neurological Diseases or Conditions, Dementia
Interventions
MemorEM
Device
Lead sponsor
eQ8Health Corporation d/b/a CareONE Concierge
Industry
Eligibility
45 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Aphasia, Primary Progressive Aphasia, Dementia, Communication, Alzheimer Disease
Interventions
Communication Bridge™
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Adrenoleukodystrophy, Batten Disease, Mucopolysaccharidosis II, Leukodystrophy, Globoid Cell, Leukodystrophy, Metachromatic, Neimann Pick Disease, Pelizaeus-Merzbacher Disease, Sandhoff Disease, Tay-Sachs Disease, Brain Diseases, Metabolic, Inborn, Alpha-Mannosidosis, Sanfilippo Mucopolysaccharidoses
Interventions
DUOC-01
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
1 Week to 22 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Healthy, Frontotemporal Dementia
Interventions
AL001, Placebo
Biological · Other
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
5
States / cities
Birmingham, Alabama • San Francisco, California • Orlando, Florida + 2 more
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effects of tDCS on Apraxia of Speech in Non-Fluent Primary Progressive Aphasia

NCT04486586
Conditions
Primary Progressive Aphasia
Interventions
Active tDCS plus Speech-Language Therapy, Sham plus Speech-Language Therapy
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 90 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Apraxia Speech
Interventions
Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Completed Not applicable Interventional Accepts healthy volunteers

WeCareAdvisor Study for Caregivers of People Living With Dementia

NCT05012410
Conditions
Dementia, Caregiver Burnout, Caregiver Stress Syndrome, Alzheimer Disease, Frontotemporal Dementia, Vascular Dementia, Dementia With Lewy Bodies
Interventions
Immediate treatment group with High-Intensity Prompts, Immediate treatment group with Low-Intensity Prompts, Waitlist Control after three months with High-Intensity Prompts, Waitlist Control after three months with Low-Intensity Prompts
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
21 Years and older
Enrollment
262 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Aphasia, Primary Progressive, Anomia, Alzheimer Disease
Interventions
Phonological, Orthographic, Semantic, Lexical, Untrained
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
40 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Conditions
Sphingomyelin Lipidosis
Interventions
Olipudase alfa
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Up to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Dementia
Interventions
QEEG-based Neurofeedback Training
Behavioral
Lead sponsor
Quietmind Foundation
Other
Eligibility
45 Years to 85 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lafayette Hill, Pennsylvania
Conditions
Parkinson Disease, Parkinsonism, Lewy Body Disease, Supranuclear Palsy, Progressive, Parkinsonism Vascular, Multiple System Atrophy, Corticobasal Degeneration, Alzheimer Disease, Frontotemporal Dementia, Primary Progressive Aphasia, Vascular Dementia
Interventions
Palliative Care
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 105 Years
Enrollment
783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
San Francisco, California • Aurora, Colorado
Conditions
Niemann-Pick Disease, Type C
Interventions
arimoclomol, Placebo
Drug
Lead sponsor
ZevraDenmark
Industry
Eligibility
2 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Oakland, California • Rochester, Minnesota
Conditions
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, PLS, Motor Neuron Disease, Lou Gehrigs Disease, Familial Disease, Amyotrophic Lateral Sclerosis, Sporadic, Muscular Dystrophy, Miyoshi Myopathy, Amyotrophic Lateral Sclerosis With Dementia
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Neurodegenerative Diseases
Interventions
Latozinemab
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Rochester, Minnesota • New York, New York + 2 more
Recruiting No phase listed Observational Accepts healthy volunteers

Tau PET in Imaging and Cognition: Healthy Adults From 55-90

NCT03372317
Conditions
Mild Cognitive Impairment, Aging
Interventions
18F-MK-6240
Drug
Lead sponsor
Yaakov Stern
Other
Eligibility
55 Years to 90 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Frontotemporal Dementia
Interventions
AL001
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more
Conditions
Behavioral Variant of Frontotemporal Dementia, Caregiver Stress Syndrome
Interventions
Health Information + Health Coaching
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers

NCT05457998
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
Flutemetamol F18 Injection, [18F]-RO6958948 Injection, [18F]-MK-6240 Injection
Diagnostic Test
Lead sponsor
Butler Hospital
Other
Eligibility
50 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island